CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price objective hoisted by analysts at Needham & Company LLC from $88.00 to $90.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price objective indicates a potential upside of 8.41% […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 15,740,000 shares, a decrease of 7.6% from the January 15th total of 17,040,000 shares. Based on an average daily volume of 2,800,000 shares, […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) was up 8.3% during trading on Thursday . The company traded as high as $85.95 and last traded at $85.62. Approximately 985,528 shares changed hands during mid-day trading, a decline of 51% from the average daily volume of 2,003,556 shares. The stock had previously closed at $79.04. […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) CEO Samarth Kulkarni sold 20,000 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $80.36, for a total transaction of $1,607,200.00. Following the transaction, the chief executive officer now directly owns 187,377 shares in the company, […]
Value Star Asset Management Hong Kong Ltd acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 17,650 shares of the company’s stock, valued at approximately $801,000. CRISPR Therapeutics comprises […]